



PRESS RELEASE

12 March 2025 12:30:00 CET

AcouSort to explore South Korean opportunities at the KIMES exhibition

AcouSort has been invited by EU Business Hub Japan and Korea to participate in their Healthcare and Medical Equipment Korea 2025 mission. The event takes place March 20-23 and provides participants with the opportunity to explore advancements in medical technology, including areas like telemedicine, AI in healthcare, and regenerative medicine, while staying informed on the latest industry trends.

The Korean life science market is vibrant and in the forefront of development of novel medical devices in the therapeutic area as well as in the diagnostic field as a result of significant investments in innovation and product development over the past years.

For AcouSort, participation in the EU Business Hub provides a great opportunity to meet and connect with Korean companies active within AcouSort's target markets. The Hub will support AcouSort with matchmaking as well as providing the company with a booth at the KIMES conference where AcouSort's products will be displayed during the exhibition.

"KIMES is the largest platform where medical professionals and influential players gather to explore the latest medical technologies and sustainable solutions. There are over 1.300 exhibitors at the event and over 70.000 visitors are expected. At AcouSort, we are absolutely thrilled to be part of this very dynamic event," says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).